Ann: CMO Appointment and Clinical Trials Update, page-85

$7,550,000 just valued DXB at 0.12 per share. IMO the dip below this price has two possible causes.

1. Smart money wants a bigger piece of the pie and are shaking out any frustrated/nervous holders. It doesn’t take much to push the price down and scare a few holders and reduce any buying competition.

2. IMO we are still fair way off any catalyst that may cause a re-rate and therefore some holders may have chosen to park their capital elsewhere with perceived limited risk of missing a re-rate.

$7,550,000 at 0.12 IMO is a very big vote of confidence for DXB.